CDK4 and CDK6 kinases: From basic science to cancer therapy

被引：165
|
作者：
Fassl, Anne [1 ]
Geng, Yan [1 ]
Sicinski, Piotr [1 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Blavatnik Inst, Dept Canc Biol,Dept Genet, Boston, MA 02215 USA
来源：
SCIENCE | 2022年 / 375卷 / 6577期
关键词：
CYCLIN-DEPENDENT KINASES; BREAST-CANCER; CELL-CYCLE; PHARMACOLOGICAL INHIBITION; TRANSCRIPTIONAL REGULATION; ACQUIRED-RESISTANCE; ANTITUMOR-ACTIVITY; ENDOCRINE THERAPY; OVARIAN-CANCER; INDUCED DEATH;
D O I：
10.1126/science.abc1495
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) and their activating partners, D-type cyclins, link the extracellular environment with the core cell cycle machinery. Constitutive activation of cyclin D-CDK4/6 represents the driving force of tumorigenesis in several cancer types. Small-molecule inhibitors of CDK4/6 have been used with great success in the treatment of hormone receptor-positive breast cancers and are in clinical trials for many other tumor types. Unexpectedly, recent work indicates that inhibition of CDK4/6 affects a wide range of cellular functions such as tumor cell metabolism and antitumor immunity. We discuss how recent advances in understanding CDK4/6 biology are opening new avenues for the future use of cyclin D-CDK4/6 inhibitors in cancer treatment.
引用
收藏
页码：158 / +
页数：20
相关论文
共 50 条
  • [41] Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
    Yang, C.
    Li, Z.
    Bhatt, T.
    Dickler, M.
    Giri, D.
    Scaltriti, M.
    Baselga, J.
    Rosen, N.
    Chandarlapaty, S.
    ONCOGENE, 2017, 36 (16) : 2255 - 2264
  • [42] Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk4/Cdk6
    Tang, Laura H.
    Contractor, Tanupriya
    Clausen, Richard
    Klimstra, David S.
    Du, Yi-Chieh Nancy
    Allen, Peter J.
    Brennan, Murray F.
    Levine, Arnold J.
    Harris, Chris R.
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4612 - 4620
  • [43] Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
    C Yang
    Z Li
    T Bhatt
    M Dickler
    D Giri
    M Scaltriti
    J Baselga
    N Rosen
    S Chandarlapaty
    Oncogene, 2017, 36 : 2255 - 2264
  • [44] Improving Breast Cancer Therapy With CDK4/6 Inhibitors
    Jaganathan, Hamsa
    Overstreet, Karen
    Reed, Elizabeth
    CLINICAL BREAST CANCER, 2014, 14 (06) : 379 - 380
  • [45] Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
    Lin, Yueh-Te
    Lin, Joseph
    Liu, Yi-En
    Hsu, Kai-Wen
    Hsieh, Chang-Chi
    Chen, Dar-Ren
    Wu, Han-Tsang
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
  • [46] The role of CDK6 in cancer
    Nebenfuehr, Sofie
    Kollmann, Karoline
    Sexl, Veronika
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (11) : 2988 - 2995
  • [47] CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
    Nardone, Valerio
    Barbarino, Marcella
    Angrisani, Antonio
    Correale, Pierpaolo
    Pastina, Pierpaolo
    Cappabianca, Salvatore
    Reginelli, Alfonso
    Mutti, Luciano
    Miracco, Clelia
    Giannicola, Rocco
    Giordano, Antonio
    Pirtoli, Luigi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [48] Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
    Glaviano, Antonino
    Wander, Seth A.
    Baird, Richard D.
    Yap, Kenneth C. -H.
    Lam, Hiu Yan
    Toi, Masakazu
    Carbone, Daniela
    Geoerger, Birgit
    Serra, Violeta
    Jones, Robert H.
    Ngeow, Joanne
    Toska, Eneda
    Stebbing, Justin
    Crasta, Karen
    Finn, Richard S.
    Diana, Patrizia
    Vuina, Karla
    de Bruin, Robertus A. M.
    Surana, Uttam
    Bardia, Aditya
    Kumar, Alan Prem
    DRUG RESISTANCE UPDATES, 2024, 76
  • [49] The role of LATS kinases in regulation of CDK4/6 in ovarian cancer.
    Saini, Siddharth
    Sesay, Fatmata
    Litovchick, Larisa
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 109 - 109
  • [50] MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma
    Bustos, Matias A.
    Ono, Shigeshi
    Marzese, Diego M.
    Oyama, Takashi
    Iida, Yuuki
    Cheung, Garrett
    Nelson, Nellie
    Hsu, Sandy C.
    Yu, Qiang
    Hoon, Dave S. B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (09) : 1955 - 1964
12345